Breaking News Instant updates and real-time market news.

GTHX

G1 Therapeutics

$28.68

0.18 (0.63%)

16:14
12/19/18
12/19
16:14
12/19/18
16:14

G1 Therapeutics to hold a conference call

Conference call to discuss the positive topline results from Phase 2 Trial of Trilaciclib will be held on December 19 at 4:30 pm. Webcast Link

GTHX G1 Therapeutics
$28.68

0.18 (0.63%)

09/18/18
NEED
09/18/18
NO CHANGE
Target $76
NEED
Buy
G1 Therapeutics price target raised to $76 from $60 at Needham
Needham analyst Chad Messer raised his price target on G1 Therapeutics to $76 and kept his Buy rating, citing the company's announcement yesterday of amended phase 2 trial protocol for trilaciclib testing in combination with chemotherapy and Tecentrq. The analyst believes that the myelopreservation data from this trial "may help bolster the available dataset" that the company is planning to bring to the FDA in the first half of 2019 for discussion regarding a viable path to approval. Messer adds that he looks forward to the "updated data from the randomized frontline SCLC trial of trilaciclib at ESMO in October".
09/17/18
HCWC
09/17/18
NO CHANGE
Target $79
HCWC
Buy
G1 Therapeutics price target raised to $79 from $61 at H.C. Wainwright
H.C. Wainwright analyst Edward White raised his price target for G1 Therapeutics to $79 saying the company, in his opinion, makes positive revision to its Phase 2 protocol in newly diagnosed small cell lung cancer patients. The analyst views the earlier availability of comprehensive myelopreservation data as a positive that could add substantially to discussions with regulators in early 2019. Following the announcement of the revised protocol, White has increased confidence in the approval of trilaciclib. He keeps a Buy rating on G1 Therapeutics.
09/10/18
BTIG
09/10/18
INITIATION
Target $80
BTIG
Buy
G1 Therapeutics assumed with a Buy at BTIG
BTIG analyst Thomas Shrader assumed G1 Therapeutics with a Buy rating and a price target of $80, citing the company's "unique" position of potentially developing two "best in class" CDK4/6 inhibitors - trilaciclib and lerociclib. The analyst notes that trilaciclib's positive outcomes support its efficacy and looks ahead to the 2nd line SCLC data later this year. Shrader adds that while the stock is no longer cheap, having risen nearly 400% since its IPO, "significant upside" in the stock price remains thanks to the "large market opportunity" of both programs that he estimates to be around $2B by 2025.
05/29/18
HCWC
05/29/18
INITIATION
Target $61
HCWC
Buy
G1 Therapeutics initiated with a Buy at H.C. Wainwright
H.C. Wainwright analyst Edward White started G1 Therapeutics with a Buy rating and $61 price target. The company's trilaciclib could improve patient outcomes by maximizing the beneficial effects of chemotherapy, while minimizing myelosuppression and immunosuppression, White tells investors in a research note. He believes investors are missing the potential of trilaciclib, which he thinks become part of the standard of care for patients with CDK4/6-independent tumors, including small cell lung cancer and triple-negative breast cancer, that receive chemotherapy.

TODAY'S FREE FLY STORIES

CDXC

ChromaDex

$3.41

0.41 (13.67%)

06:41
10/17/19
10/17
06:41
10/17/19
06:41
Hot Stocks
ChromaDex reports new study on nicotinamide riboside importance »

ChromaDex announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BC

Brunswick

$55.47

0.46 (0.84%)

06:39
10/17/19
10/17
06:39
10/17/19
06:39
Downgrade
Brunswick rating change  »

Longbow downgrades…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Oct

MTB

M&T Bank

$159.14

0.27 (0.17%)

06:38
10/17/19
10/17
06:38
10/17/19
06:38
Earnings
M&T Bank reports Q3 EPS $3.47, consensus $3.57 »

Reports Q3 common…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Oct

NEPT

Neptune Wellness

$3.49

0.03 (0.87%)

06:38
10/17/19
10/17
06:38
10/17/19
06:38
Hot Stocks
Neptune Wellness to provide extraction services to farming services operation »

Neptune Wellness…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Nov

NSRGY

Nestle

$0.00

(0.00%)

06:38
10/17/19
10/17
06:38
10/17/19
06:38
Hot Stocks
Nestle says portfolio management 'fully on track' »

Nestle notes that the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SNA

Snap-On

$157.68

-0.64 (-0.40%)

06:37
10/17/19
10/17
06:37
10/17/19
06:37
Hot Stocks
Snap-On sees 2019 CapEx $95M-$105M »

Sees 2019 effective…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Oct

NSRGY

Nestle

$0.00

(0.00%)

06:37
10/17/19
10/17
06:37
10/17/19
06:37
Earnings
Nestle backs underlying FY19 EPS in constant currency up vs. last year »

Full-year guidance for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NSRGY

Nestle

$0.00

(0.00%)

06:37
10/17/19
10/17
06:37
10/17/19
06:37
Earnings
Nestle reports nine month sales CHF68.367B vs. CHF66.424B last year »

Organic growth reached…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KEY

KeyCorp

$17.70

-0.08 (-0.45%)

06:35
10/17/19
10/17
06:35
10/17/19
06:35
Earnings
KeyCorp reports Q3 ex-items EPS 48c, consensus 46c »

Reports Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Oct

HON

Honeywell

$163.86

0.2 (0.12%)

06:35
10/17/19
10/17
06:35
10/17/19
06:35
Earnings
Honeywell narrows FY19 EPS view to $8.10-$8.15 from $7.95-$8.15, consensus $8.09 »

Narrows FY19 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Oct

NSRGY

Nestle

$0.00

(0.00%)

06:34
10/17/19
10/17
06:34
10/17/19
06:34
Hot Stocks
Nestle to distribute CHF20B to shareholders via share buybacks »

Nestle's Board of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NBEV

New Age Beverages

$3.07

0.335 (12.27%)

, NSRGY

Nestle

$0.00

(0.00%)

06:34
10/17/19
10/17
06:34
10/17/19
06:34
Hot Stocks
New Age Beverages partners with Nestle to relaunch NESTEA in U.S. »

New Age Beverages (NBEV)…

NBEV

New Age Beverages

$3.07

0.335 (12.27%)

NSRGY

Nestle

$0.00

(0.00%)

KO

Coca-Cola

$53.49

-0.02 (-0.04%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Oct

TSM

TSMC

$50.14

-0.28 (-0.56%)

06:33
10/17/19
10/17
06:33
10/17/19
06:33
Hot Stocks
Breaking Hot Stocks news story on TSMC »

TSMC sees FY19 CapEx…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Oct

TSM

TSMC

$50.14

-0.28 (-0.56%)

06:33
10/17/19
10/17
06:33
10/17/19
06:33
Earnings
TSMC sees Q4 revenue $10.2B-$10.3B, consensus $9.63B »

Gross profit margin is…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Oct

HON

Honeywell

$163.86

0.2 (0.12%)

06:33
10/17/19
10/17
06:33
10/17/19
06:33
Earnings
Honeywell reports Q3 adj. EPS $2.08, consensus $2.01 »

Reports Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Oct

TSM

TSMC

$50.14

-0.28 (-0.56%)

06:32
10/17/19
10/17
06:32
10/17/19
06:32
Earnings
TSMC reports Q3 EPS 62c, consensus 60c »

Reports Q3 revenue $9.4B,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Oct

TXT

Textron

$50.52

-0.15 (-0.30%)

06:32
10/17/19
10/17
06:32
10/17/19
06:32
Earnings
Textron narrows FY19 EPS view to $3.70-$3.80 from $3.65-$3.85, consensus $3.74 »

The company revised its…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Oct

NFLX

Netflix

$286.83

2.59 (0.91%)

06:31
10/17/19
10/17
06:31
10/17/19
06:31
Recommendations
Netflix analyst commentary  »

Netflix price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Oct

SNA

Snap-On

$157.68

-0.64 (-0.40%)

06:31
10/17/19
10/17
06:31
10/17/19
06:31
Earnings
Snap-On reports Q3 EPS $2.96, consensus $2.94 »

Reports Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Oct

TXT

Textron

$50.52

-0.15 (-0.30%)

06:30
10/17/19
10/17
06:30
10/17/19
06:30
Earnings
Textron reports Q3 EPS 95c, consensus 85c »

Reports Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Oct

IBM

IBM

$142.04

-0.94 (-0.66%)

06:29
10/17/19
10/17
06:29
10/17/19
06:29
Recommendations
IBM analyst commentary  »

IBM price target lowered…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Oct

MNST

Monster Beverage

$56.54

0.27 (0.48%)

06:28
10/17/19
10/17
06:28
10/17/19
06:28
Downgrade
Monster Beverage rating change  »

Monster Beverage…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FB

Facebook

$189.62

0.81 (0.43%)

, PYPL

PayPal

$103.11

-0.43 (-0.42%)

06:28
10/17/19
10/17
06:28
10/17/19
06:28
Periodicals
Facebook's Marcus says Libra 'absolutely not' in jeopardy, Yahoo Finance reports »

Facebook's (FB)…

FB

Facebook

$189.62

0.81 (0.43%)

PYPL

PayPal

$103.11

-0.43 (-0.42%)

EBAY

eBay

$38.91

0.03 (0.08%)

BKNG

Booking Holdings

$2,028.24

10.61 (0.53%)

V

Visa

$177.87

-0.93 (-0.52%)

MA

MasterCard

$278.40

-0.24 (-0.09%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Oct

  • 23

    Oct

  • 23

    Oct

  • 23

    Oct

  • 24

    Oct

  • 27

    Oct

  • 29

    Oct

  • 29

    Oct

  • 30

    Oct

NFLX

Netflix

$286.83

2.59 (0.91%)

06:27
10/17/19
10/17
06:27
10/17/19
06:27
Recommendations
Netflix analyst commentary  »

Netflix reported a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Oct

MAT

Mattel

$11.50

0.105 (0.92%)

, WMT

Walmart

$119.44

-0.08 (-0.07%)

06:24
10/17/19
10/17
06:24
10/17/19
06:24
Periodicals
Walmart, Mattel 'lease floors' in KidHQ interactive store, WSJ reports »

Mattel (MAT) and Walmart…

MAT

Mattel

$11.50

0.105 (0.92%)

WMT

Walmart

$119.44

-0.08 (-0.07%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Oct

  • 13

    Nov

  • 14

    Nov

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.